Insights with impact

Lars Van Der Veen
Industry Insight

Targeting the inactive state: A new chapter in PI3Kδ inhibition

 Man With Beaker
Industry Insight

The biology of roginolisib: Activity without immune toxicity

 Catherine Pickering
Industry Insight

End of year reflections from our CEO

 National Cancer Institute Sp2c8o2ezbw Unsplash
Industry Insight

Driving breakthroughs for myelofibrosis care

 Lars Van Der Veen
Industry Insight

What’s next for cambritaxestat?

 National Cancer Institute Lnvcexqwc O Unsplash
Industry Insight

Realizing the potential of PI3Kδ inhibitors in peripheral T-cell lymphomas

 Michelle 1000x882 New
Industry Insight

iOnctura expands roginolisib trials to the US

 Catherine Pickering
Industry Insight

iOnctura enhances board to accelerate growth and innovation

 Michael Lahn 819x1024
Industry Insight

Addressing drug resistance in non-small cell lung cancer

 Eye2
Industry Insight

Scientific innovation in uveal melanoma

 Microscope 819x1024
Industry Insight

Opportunities and challenges in oncology immunotherapy

 Catherine Pickering
Industry Insight

Reflections from our CEO

 National Cancer Institute Mq2udwkzgim Unsplash Copy
Industry Insight

Pancreatic cancer – our commitment to scientific advances

 Giusy di Conza
Industry Insight

A bold new era in global cancer drug discovery

 Catherine Pickering
Industry Insight

A note from our CEO

 Giusy Di Conza Comp 2
Industry Insight

Realising the potential of autotaxin therapy in cancer

 Pexels Thirdman 7659470
Industry Insight

PI3Kδ inhibitors offer serious promise in solid tumors

 Michael Lahn 819x1024
Industry Insight

Emerging therapies offer hope for uveal melanoma patients
iOnctura
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.